Skip to main content
TipRanks
Go Ultimate75% OFF

Aelis Farma SA (AELIS) AI Stock Analysis

3 Followers
FR:AELIS

Aelis Farma SA

(Paris:AELIS)

Select Model
Rating:43Neutral
Price Target:EUR 0.83â–¼(-9.67% Downside)
Action:upgraded
Date:11/11/26

The score is primarily constrained by very weak financial performance, including persistent losses, equity erosion, and cash burn. Mixed technical momentum provides limited support, while the negative P/E further weakens the outlook. Earnings-call and corporate-event components were excluded because no usable data was provided.

Positive Factors
Endocannabinoid Therapeutic FocusA focused small-molecule platform targeting the endocannabinoid system gives Aelis Farma a defined scientific identity and potential to build expertise across related neurological and peripheral indications. This specialization can support durable pipeline development if clinical outcomes validate the approach.
Negative Factors
Declining Revenue BaseRecent revenue contraction weakens the company’s ability to support its operating structure through internally generated income. Revenue remaining well below 2023 levels also indicates that the business has not established a stable commercial trajectory, increasing reliance on future development success or external financing.

Aelis Farma SA (AELIS) vs. iShares MSCI France ETF (EWQ)

-50%-25%0%25%50%75%100%FR:AELIS-16.36%EWQ+2.16%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 12.54M
Dividend Yield
―
Average Volume (3M)
20.71K
Price to Earnings (P/E)
-2.8
Beta (1Y)
0.73
Revenue Growth
-97.09%
EPS Growth
45.00%
Country
France
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aelis Farma SA Business Overview & Revenue Model

Company Description

Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-speci...

Aelis Farma SA Financial Statement Overview

Summary

Financial performance is materially weak: revenue contracted sharply, losses widened, equity eroded, and operating cash flow remained negative. The underlying average of the provided financial scores is below the permitted minimum, so the score is set to 37.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.64M2.08M2.68M9.05M3.81M9.07M
Gross Profit-3.10M-279.00K2.68M9.05M3.81M9.07M
EBITDA-7.08M-8.00M-7.18M-6.35M-16.23M844.00K
Net Income-4.52M-6.43M-7.46M-5.08M-14.29M574.00K
Balance Sheet
Total Assets8.44M12.05M19.71M26.28M39.22M28.31M
Cash, Cash Equivalents and Short-Term Investments6.62M8.21M14.05M20.23M34.40M24.71M
Total Debt4.38M6.60M6.25M4.04M3.82M6.41M
Total Liabilities6.12M7.61M9.59M13.08M19.43M27.41M
Stockholders Equity2.31M4.44M10.12M13.20M19.79M899.00K
Cash Flow
Free Cash Flow-3.48M-5.39M-11.72M-12.67M-13.19M18.76M
Operating Cash Flow-3.48M-5.38M-11.53M-12.59M-13.05M18.97M
Investing Cash Flow-837.00K-841.00K-190.00K-88.00K-86.00K-212.00K
Financing Cash Flow-703.00K538.00K5.81M-1.34M22.10M180.00K

Aelis Farma SA Technical Analysis

Technical Analysis SentimentPositive
Last Price0.92

Price Trends

50DMA0.84Positive
100DMA0.94Negative
200DMA1.10Negative

Market Momentum

MACD0.02Negative
RSI60.72Neutral
STOCH41.47Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AELIS, the sentiment is Positive. The current price of 0.92 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.84, and below the 200-day MA of 1.10, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.72 is Neutral, neither overbought nor oversold. The STOCH value of 41.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AELIS.

Aelis Farma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:AELIS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:POXELFR:POXEL46NeutralEUR 7.83M-0.3833.88%―――
FR:AELISFR:AELIS43NeutralEUR 12.61M-2.79――-97.09%45.00%
FR:SIGHTFR:SIGHT43NeutralEUR 18.44M-1.0352.39%―-610.31%43.88%
FR:ALBPSFR:ALBPS42NeutralEUR 14.54M-0.02153.48%――90.97%
FR:ALDVIFR:ALDVI39UnderperformEUR 9.55M220.16-0.18%―0.10%99.69%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%FR:AELISFR:POXELFR:SIGHTFR:ALDVIFR:ALBPSFR:ALNFLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:AELIS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:AELISAelis Farma SA0.92-0.17-15.60%
FR:POXELPoxel SA0.14-0.12-44.87%
FR:SIGHTGenSight Biologics0.07-0.03-27.18%
FR:ALDVIAdvicenne SA0.66-0.95-59.10%
FR:ALBPSBiophytis SA0.04-0.05-56.47%
FR:ALNFLNFL Biosciences SA0.35-0.54-60.34%

Aelis Farma SA Corporate Events

Aelis Farma Reports Caregiver-Observed Benefits for AEF0217

Nov 6, 2026

Aelis Farma is a clinical-stage biopharmaceutical company developing CB1 receptor treatments for cognitive impairments and related conditions. Its lead candidate, AEF0217, is a first-in-class signaling-specific CB1 inhibitor with a development focus...

Aelis Farma Publishes 2026 Half-Year Financial Report

Sep 24, 2026

Aelis Farma announced that its 2026 half-year financial report has been filed with the French Financial Markets Authority and is now available to the public on the company’s website. The publication offers investors and stakeholders updated visibilit...

Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances

Sep 15, 2026

In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the international Phase 2b trial of AEF0217 in people with Down syndrome, with recruitment on track and a positive safety committee recommendation. A key regulatory...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026